食品及药物管理局已停止PepGen计划 开始第二阶段的试验 在美国的Duchenne肌肉萎缩症治疗。 The FDA has halted PepGen's plan to begin a phase 2 trial for Duchenne muscular dystrophy treatment in the U.S.

食品和药物管理局对PepGen计划进行临床检查,以开始美国Duchenne肌肉萎缩(DMD)治疗(PGN-EDO51)的第二阶段试验。 The FDA has placed a clinical hold on PepGen's plans to start a phase 2 trial for its Duchenne muscular dystrophy (DMD) treatment, PGN-EDO51, in the U.S. 公司预计将在30天内收到FDA的详细保留信. The company expects to receive a detailed hold letter from the FDA within 30 days. 尽管被搁置，但该研究已经在英国进行。受此消息影响，PepGen 的股价在盘前交易中下跌了 29%。 Despite the hold, the study is already underway in the U.K. PepGen's stock dropped 29% in premarket trading on this news.